Auna (NYSE:AUNA) Director John Wilton Sells 17,574 Shares of Stock

Auna S.A. (NYSE:AUNA) Director John Wilton sold 17,574 shares of Auna stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $4.17, for a total value of $73,283.58. Following the completion of the transaction, the director owned 49,974 shares in the company, valued at $208,391.58. This represents a 26.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Auna Trading Up 9.4%

Shares of NYSE:AUNA opened at $4.54 on Tuesday. Auna S.A. has a 12-month low of $4.09 and a 12-month high of $6.85. The business’s fifty day simple moving average is $5.20 and its 200-day simple moving average is $5.01. The company has a market capitalization of $336.01 million, a PE ratio of 17.46 and a beta of 0.82. The company has a current ratio of 1.09, a quick ratio of 1.00 and a debt-to-equity ratio of 1.76.

Auna (NYSE:AUNA) last announced its quarterly earnings results on Friday, May 15th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.14). Auna had a net margin of 1.53% and a return on equity of 16.25%. The company had revenue of $336.84 million during the quarter, compared to analysts’ expectations of $320.54 million. As a group, equities research analysts predict that Auna S.A. will post 0.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on AUNA shares. JPMorgan Chase & Co. cut their price target on Auna from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Tuesday, May 26th. Zacks Research downgraded Auna from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Wall Street Zen downgraded Auna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Auna in a research note on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Auna presently has a consensus rating of “Hold” and a consensus price target of $6.97.

Institutional Trading of Auna

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AUNA. Renaissance Technologies LLC lifted its holdings in shares of Auna by 487.7% in the 1st quarter. Renaissance Technologies LLC now owns 668,457 shares of the company’s stock valued at $3,683,000 after buying an additional 554,707 shares during the period. Marshall Wace LLP lifted its holdings in shares of Auna by 391.0% in the 4th quarter. Marshall Wace LLP now owns 162,992 shares of the company’s stock valued at $802,000 after buying an additional 129,799 shares during the period. Lazard Asset Management LLC acquired a new position in shares of Auna in the 1st quarter valued at about $557,000. Goldman Sachs Group Inc. lifted its holdings in shares of Auna by 43.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 71,645 shares of the company’s stock valued at $352,000 after buying an additional 21,579 shares during the period. Finally, Hsbc Holdings PLC acquired a new position in shares of Auna in the 1st quarter valued at about $324,000.

About Auna

Auna, listed on the New York Stock Exchange under the ticker symbol AUNA, is a Peruvian integrated healthcare services company headquartered in Lima. The firm operates a diversified care network that spans hospitals, outpatient medical centers, diagnostic imaging and laboratory facilities, as well as optical and dental clinics. Auna’s organizational structure is designed to support a continuum of care model, offering both general and specialized treatments across multiple touchpoints.

The company delivers a broad range of clinical services, including emergency care, inpatient and outpatient surgery, obstetrics, cardiology, oncology, orthopedics, and other specialized disciplines.